253 related articles for article (PubMed ID: 20542796)
21. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.
Hall R; Mazer CD
Anesth Analg; 2011 Feb; 112(2):292-318. PubMed ID: 21212258
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of hirudins in percutaneous coronary intervention and the risk of Kounis syndrome.
Kounis NG; Kounis SA; Kounis GN; Hahalis G
Catheter Cardiovasc Interv; 2009 Mar; 73(4):584-5. PubMed ID: 19085914
[No Abstract] [Full Text] [Related]
23. Antiplatelet therapy: anti-ischemic benefits versus bleeding risk.
Gibson CM
J Interv Cardiol; 2008 Dec; 21 Suppl 1():S3-9. PubMed ID: 19090934
[TBL] [Abstract][Full Text] [Related]
24. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
Sabatier B; Trinquart L; Emmerich J
Arch Cardiovasc Dis; 2010 Oct; 103(10):497-501. PubMed ID: 21130962
[No Abstract] [Full Text] [Related]
25. Evidence-based management of patients undergoing PCI: stent controversies.
Vetrovec GW
Catheter Cardiovasc Interv; 2010 Mar; 75 Suppl 1():S39-42. PubMed ID: 20333706
[TBL] [Abstract][Full Text] [Related]
26. Antithrombotic therapy use after percutaneous coronary intervention and stent implantation in patients taking chronic oral anticoagulation.
Ruiz-Nodar JM; Marín F; Lip GY
JACC Cardiovasc Interv; 2008 Jun; 1(3):329; author reply 330-1. PubMed ID: 19463322
[No Abstract] [Full Text] [Related]
27. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
[TBL] [Abstract][Full Text] [Related]
28. [Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
Saidi Y; Guesmi F; Landolsi M; Trabelsi S; Khemiri K; Ounalli K; Dziri C; Houissa M
Tunis Med; 2010 Jan; 88(1):63-4. PubMed ID: 20419882
[No Abstract] [Full Text] [Related]
29. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.
Manoukian SV
Am J Cardiol; 2009 Sep; 104(5 Suppl):9C-15C. PubMed ID: 19695355
[TBL] [Abstract][Full Text] [Related]
30. Off-label use and the spectre of drug-eluting stent thrombosis.
Cook S; Wenaweser P
Circ Cardiovasc Interv; 2009 Aug; 2(4):273-6. PubMed ID: 20031728
[No Abstract] [Full Text] [Related]
31. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Wiviott SD
Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Thomas D; Giugliano RP
Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
[TBL] [Abstract][Full Text] [Related]
33. Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention.
Tan VP; Yan BP; Kiernan TJ; Ajani AE
Cardiovasc Revasc Med; 2009; 10(1):36-44. PubMed ID: 19159853
[TBL] [Abstract][Full Text] [Related]
34. Prasugrel in clinical practice.
Bhatt DL
N Engl J Med; 2009 Sep; 361(10):940-2. PubMed ID: 19605807
[No Abstract] [Full Text] [Related]
35. Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Moussa ID; Colombo A
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1047-54. PubMed ID: 19626692
[TBL] [Abstract][Full Text] [Related]
36. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
37. Drug eluting stents in AMI: keep the data coming.
Vetrovec GW
Catheter Cardiovasc Interv; 2008 May; 71(6):770-1. PubMed ID: 18412075
[No Abstract] [Full Text] [Related]
38. Incidence, outcomes, and management of bleeding in non-ST-elevation acute coronary syndromes.
Gutierrez A; Rao SV
Cleve Clin J Med; 2010 Jun; 77(6):369-79. PubMed ID: 20516248
[TBL] [Abstract][Full Text] [Related]
39. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Helft G; Gilard M; Le Feuvre C; Zaman AG
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):673-80. PubMed ID: 17122800
[TBL] [Abstract][Full Text] [Related]
40. Dual antiplatelet therapy plus oral anticoagulation: how does hemorrhagic risk impact stent selection?
Giugliano GR; Lotfi AS
JACC Cardiovasc Interv; 2008 Jun; 1(3):330; author reply 330-1. PubMed ID: 19463324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
